New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

LB Pharmaceuticals Inc (LBRX) vs Novavax, Inc. (NVAX)

LB Pharmaceuticals Inc and Novavax, Inc. are both Biotechnology companies. LB Pharmaceuticals Inc and Novavax, Inc. are of similar size ($1.3B and $1.3B). LB Pharmaceuticals Inc has the higher net margin (0.00% vs −18.6%) and the lower return on invested capital (−686.2% vs 0.00%). Across the 12 metrics below, Novavax, Inc. leads on 7 and LB Pharmaceuticals Inc on 5.

Valuation

Metric LBRX NVAX Biotechnology median
P/E n/m n/m 8.26
P/S n/m 3.10 9.20
P/B 3.17 n/m 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m n/m 0.67
EV/Sales n/m 2.30 9.05
Earnings yield (11.54%) (5.95%) (34.24%)
Free cash flow yield (10.86%) (19.23%) (24.77%)

Profitability

Metric LBRX NVAX Biotechnology median
Gross margin — 78.01% 70.18%
Operating margin 0.00% (21.23%) 0.00%
Net margin 0.00% (18.64%) 0.00%
Free cash flow margin 0.00% (59.09%) 0.00%
Return on equity (38.80%) 41.08% (51.58%)
Return on assets (36.48%) (7.42%) (45.91%)
Return on invested capital (686.18%) 0.00% 0.00%

Growth

Metric LBRX NVAX Biotechnology median
Revenue growth (TTM) — (61.33%) 7.20%
EPS growth (last fiscal year) 98.22% 309.76% 29.04%
Revenue growth, 5-year CAGR — 18.76% 9.48%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LBRX NVAX Biotechnology median
Debt to equity 0.00 (1.35) 0.00
Current ratio 14.78 2.15 4.83
Net debt to EBITDA 9.90 (1.04) 1.01

Dividend

Metric LBRX NVAX Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric LBRX NVAX Biotechnology median
Market cap 1.30b 1.27b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack